United States Patent 9,891,239 Scope, Claim Coverage, and US Patent Landscape (Emtricitabine/Elvitegravir ± Tenofovir Disoproxil Fumarate HIV Compositions)
Executive summary
US 9,891,239 is directed to broad HIV antiviral product claim coverage in the United States for oral pharmaceutical compositions containing emtricitabine (FTC) plus elvitegravir (EVG), with dependent fallback to adding tenofovir disoproxil fumarate (TDF). It also covers method-of-use treatment claims using those compositions to treat HIV infection. This claim set is formulation-light and does not require specific salts, polymorphs, dosing regimens, or co-formulation architecture in the independent claim language provided. That structure typically increases the risk that generic or “component-combination” products can fall within scope if they practice the same ingredient set and dosage form, while narrowing patent leverage around any one specific proprietary process or formulation variant.
No additional patent numbers, prosecution history details, assignee, expiration, or Orange Book listings were provided here, so the analysis below is limited to what can be concluded from the claim language itself.
What is US Patent 9,891,239 claim scope for emtricitabine and elvitegravir HIV compositions?
Short answer (claim 1): US 9,891,239 claim 1 covers an HIV pharmaceutical composition that contains emtricitabine and elvitegravir and at least one pharmaceutically acceptable carrier/excipient.
What does “pharmaceutical composition comprising” mean for infringement scope?
Claim 1 uses open-ended transitional language (“comprising”). In US claim construction, “comprising” generally means the product may include the required elements plus additional components that do not remove the required composition elements.
Implications:
- Products containing FTC + EVG plus excipients (and potentially other HIV antivirals, unless claim construction or the rest of the specification limits “composition” to particular combinations) can still fall within claim 1 as long as they contain FTC and EVG and a pharmaceutically acceptable carrier.
- The claim is not limited by:
- fixed ratios
- specific excipient lists
- particle size/polymorph
- coating type
- capsule/tablet identity (unless the specification later narrows the claim, which cannot be concluded from the claim text provided)
Is the carrier/excipient limitation narrow enough to avoid generic entry?
The “pharmaceutically acceptable carrier or excipient” element is usually broad in scope. It typically covers almost any oral solid or liquid formulation components permitted in pharmaceuticals.
Implications:
- This limitation rarely creates a meaningful design-around for generic manufacturers.
- The practical infringement question usually turns on whether a product contains FTC and EVG together as formulated and dosed.
Does claim 1 cover free drug substances vs. specific salt forms?
The claim text says “emtricitabine” and “elvitegravir” without specifying salts or hydrate states. From claim scope logic:
- If a product uses a salt form, it still falls under the ingredient identity unless the patent specification or prosecution history restricts it. That restriction cannot be determined from the claim language alone.
Does claim 2 broaden or narrow US 9,891,239 coverage with tenofovir disoproxil fumarate?
Short answer (claim 2): Claim 2 depends on claim 1 and adds tenofovir disoproxil fumarate. It covers compositions containing FTC + EVG + TDF plus a pharmaceutically acceptable carrier/excipient.
How dependency affects infringement
Because claim 2 is dependent on claim 1, infringement requires:
- all elements of claim 1 (FTC + EVG + carrier)
- plus TDF
So claim 2 is narrower than claim 1 but more specific for the classic multi-drug HIV regimen pattern.
Commercial relevance of the FTC/EVG/TDF triad
In the HIV combination market, compositions that include FTC, EVG, and TDF are commonly aligned with “fixed-dose combination” strategies. If a US-marketed product or generic product contains that triad in one pharmaceutical composition, claim 2 creates direct coverage pressure.
What is the method-of-use scope for treating HIV under US 9,891,239 claims 3 and 4?
Short answer (claims 3 and 4):
- Claim 3 covers a method of treating HIV infection by administering a therapeutically effective amount of the claim 1 composition (FTC + EVG).
- Claim 4 covers a similar method using the claim 2 composition (FTC + EVG + TDF).
How method claims shift the infringement “who” problem
Composition claims can be infringed by manufacturing or sale of a covered product. Method-of-use claims can focus on administration by healthcare providers and/or induced infringement theories in litigation.
Key practical implications:
- If a covered composition is prescribed and administered, method-of-use claims can become relevant even when the product’s label and prescribing information are controlled by regulatory submissions.
- Induced infringement and active inducement frameworks can matter depending on how a generic’s label directs use of the covered combination.
“Treating an HIV infection” breadth
The phrase “treating an HIV infection” is broad. It likely covers:
- reducing viral load
- improving immune function
- delaying progression to AIDS
- other recognized clinical endpoints for HIV treatment
Claim text does not limit patient population (treatment-naïve vs. treatment-experienced), regimen line, or viral genotype.
What exact “combination ingredients” does US 9,891,239 cover and what is the design-around logic?
Ingredient coverage map
| Claim |
Required active ingredients |
Additional drug requirements |
Carrier/excipient required |
| 1 |
emtricitabine + elvitegravir |
none stated |
yes |
| 2 |
emtricitabine + elvitegravir + tenofovir disoproxil fumarate |
TDF required |
yes |
| 3 |
claim 1 composition administered for HIV treatment |
none stated |
yes (via administered composition) |
| 4 |
claim 2 composition administered for HIV treatment |
TDF required |
yes (via administered composition) |
Most plausible design-around levers
Given the ingredient-centric claim language:
- Removing elvitegravir from the co-formulation removes claim coverage for both claim 1 and claim 2.
- Keeping elvitegravir but removing emtricitabine removes coverage for both claims.
- Keeping FTC + EVG but omitting TDF may avoid claim 2 while remaining exposed to claim 1 and method claim 3.
The claim text does not allow much “formulation-only” escape because the carrier/excipient element is broad.
How does US 9,891,239 compare with typical HIV fixed-dose combination patent patterns?
Formulation-limited vs. ingredient-limited claim strategies
Many HIV patents are drafted to secure narrow protection around:
- specific salts (e.g., cobicistat salt analogs or particular tenofovir forms)
- polymorphs/crystalline forms
- coating matrices or sustained-release profiles
- manufacturing processes (granulation, drying, compression conditions)
- dosing regimen rules (timing constraints, food effects)
US 9,891,239 claim language provided looks ingredient-combination-centric, which is a higher-value position for infringement leverage against any product containing the same ingredient set.
Method claims often track composition claims
Claims 3 and 4 mirror claims 1 and 2, which is common when the patent holder expects the composition to be administered in routine clinical HIV care.
What is the likely scope for generics and “authorized generics” for US 9,891,239?
Short answer: A generic product that includes the covered ingredient combination can face direct composition-claim exposure, and routine prescription/administration can trigger method claim exposure.
Key generic-entry risk points based on claim text
- ANDA or 505(j) paragraph IV strategies: If a generic files to market a product that contains FTC + EVG (claim 1) and/or FTC + EVG + TDF (claim 2), the patent is structurally positioned for challenge or assertion.
- Labeling and instructions: Even if composition is arguably infringed by manufacturing/sale, method-of-use exposure can be tied to labeling that directs administration of the covered combination for HIV treatment.
Regulatory pathway interaction
Claim text alone cannot determine whether a patent is listed in the FDA Orange Book for a specific NDA product. In litigation, the practical enforcement posture often follows whether the patent is tied to:
- an NDA for a fixed-dose combination drug
- a specific dosage form
- specific strength(s)
Those links require Orange Book and assignment data, which are not provided here.
How strong is the patent estate for this claim set based on coverage breadth?
Short answer: Based solely on the claim language provided, strength is driven by breadth of ingredients and broad therapeutic purpose, with limited narrowing elements.
Strength indicators from the claim text
- Low structural limitation: carrier/excipient is generic and usually satisfied.
- Clear ingredient requirements: infringement hinges on FTC/EVG (and TDF for claim 2), which are easy to verify chemically in accused products.
- Method claims are aligned with real-world use: “treating HIV infection” does not impose complex clinical inclusion criteria.
Strength detractors from the claim text
- If the specification contains narrower embodiments (not shown here), courts can limit claim interpretation. Without that text, this cannot be assessed.
- Ingredient-only claims can face validity challenges if they overlap with known prior art combinations (again requires bibliographic and prosecution context that is not included here).
What patents might “cluster” around US 9,891,239 in HIV FTC/EVG/TDF landscapes?
Short answer: The most common adjacent US patent clusters in FTC/EVG-based programs include:
- earlier composition patents covering FTC/EVG or FTC/EVG/TDF
- patents targeting additional co-formulated drugs (often pharmacokinetic boosters in EVG regimens, though the claim text here does not mention any booster)
- formulation and manufacturing patents for tablets/capsules
- method-of-use patents for particular treatment populations or endpoints
However, no additional patent numbers, publication IDs, or assignee names were provided, so no specific citations or counts can be produced without inventing data.
Key Takeaways
- Claim 1 covers a pharmaceutical composition containing emtricitabine + elvitegravir with a pharmaceutically acceptable carrier/excipient.
- Claim 2 is a dependent narrowing: emtricitabine + elvitegravir + tenofovir disoproxil fumarate plus a carrier/excipient.
- Claims 3 and 4 add method-of-use coverage for administering those compositions to treat HIV infection, without limiting patient subgroup or regimen line.
- The claim structure is ingredient-centric and has limited formulation escape within the carrier/excipient element, making product ingredient composition the primary infringement and design-around axis.
FAQs
- Can a product containing FTC and EVG but no TDF infringe US 9,891,239 claim 1 and claim 3?
- Does US 9,891,239 require a specific dosage form (tablet vs capsule) based on the provided claim language?
- What is the difference in infringement risk between practicing claim 1-compositions versus claim 2-compositions?
- How do method-of-use claims typically affect Paragraph IV generic challenges for combination HIV therapies?
- What kinds of pharmaceutical changes most effectively avoid coverage when a patent’s claim is limited to ingredient combinations plus a carrier?
References
No external sources were provided or cited.
